Preview
Patients who are both obese and hypertensive are at increased risk for left ventricular hypertrophy and its consequences, including morbid cardiac events. What factors contribute to development of left ventricular hypertrophy? Which pharmacologic agents may be ideal for treatment and why? What nonpharmacologic strategies should be emphasized? The authors address these questions, citing findings from their own research and numerous studies in the literature.